<DOC>
	<DOCNO>NCT01393223</DOCNO>
	<brief_summary>The purpose study assess safety tolerability two dos LP08 compare placebo . Hypothesis : Safety LP-08 therapy significantly different placebo group . Secondary Efficacy Endpoints : A matched-pair data analysis design employ , i.e . measure outcomes subject ' improvement quantitative qualitative measure disease condition assess prior LP-08 instillation four eight week follow-up visit</brief_summary>
	<brief_title>Evaluation Intravesical LP08 Patients With Interstitial Cystitis/Painful Bladder Syndrome</brief_title>
	<detailed_description>This single-center , dose-ranging , placebo-controlled , double-blind , randomized study include male female subject interstitial cystitis/bladder pain syndrome ( IC/BPS ) determine physician use current diagnostic criterion IC/BPS . A total 36 subject enrol five ( 5 ) study sit U.S. Enrollment expect complete within one year initiating study . The study comprise two part . The first part study dose-ranging , randomize , double-blind , placebo-controlled study evaluate safety , tolerability efficacy LP-08 20 mg 80 mg dos compare placebo . The second part study Open Label Extension study safety , tolerability efficacy LP-08 80 mg . Subjects randomize placebo control group must complete randomized portion study , include eight week follow-up period , eligible Open Label Extension .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Cystitis</mesh_term>
	<mesh_term>Cystitis , Interstitial</mesh_term>
	<criteria>A patient deem suitable inclusion study patient meet follow criterion : 1 . Male female least 18 year age 2 . IC/BPS diagnose health care provider base follow criterion : Complaint suprapubic pain related bladder filling , accompany symptom increase daytime night time frequency , absence proven urinary infection obvious pathology Have IC/BPS symptom least six month Score â‰¥ 12 ICSI/PI baseline Urinary frequency &gt; 10 time day selfreport confirm baseline threeday void diary Have IC/BPS judgment investigator stable previous 30 day IC/BPSrelated pain define score &gt; 3 cm &lt; 9 cm pain VAS 0 pain 10 maximum pain 3 . Have inadequate clinical response conservative treatment , may include one follow : 1 ) time void behavioral modification therapy , 2 ) dietary restriction , 3 ) stress reduction and/or 5 ) oral therapy follow medication : Antidepressants Antihistamines Antimuscarinic anticholinergic agent Alpha adrenergic blocker Analgesics Pentosan polysulfate 4 . Women childbearing potential : negative urine pregnancy test screening , must agree use acceptable contraception ( oral contraceptive , intrauterine double barrier method ) , agree investigator , study period 5 . Provide sign informed consent 6 . Subject agree available followup evaluation require protocol Patients exclude enrollment study follow true : 1 . Currently pregnant breastfeeding , plan become pregnant course study 2 . Have receive investigational product device within 30 day prior screen visit 3 . Have receive intravesical therapy bladder hydrodistention within 30 day prior screen visit . Intravesical instillation may include liquid drug delivery device , pentosan polysulfate sodium , lidocaine , steroid , heparin , chondroitin combination additional formulation . 4 . Have participate IC/BPS research trial within 90 day prior screen visit return baseline participate IC/BPS research trial great 90 day prior screen visit 5 . Have receive following medication within 30 day screen visit , unless medication administer stable dose month expect remain stable dose throughout study : Antidepressants Antihistamines ( use antihistamine need allergy allow ) Anticonvulsants Antimuscarinic anticholinergic agent Alpha adrenergic blocker Pentosan polysulfate sodium Oral chondroitin 6 . Have indicate use &gt; 70 mg morphine equivalent opioids per week control IC/BPS pain within 30 day prior screen , expect require level IC/BPS pain control study period 7 . Previous augmentation cystoplasty , cystectomy , neurectomy ( i.e. , hypogastric nerve plexus ablation ) . Bladder botulinum toxin injection within nine month prior screen . 8 . Sacral and/or pudendal nerve neuromodulation device ( Interstim ) within last 6 month . Subjects would exclude Interstim great 6 month ago stable set within past 90 day 9 . Percutaneous Tibial Nerve Stimulation ( PTNS ) treatment within past 90 day 10 . Evidence renal impairment ( creatinine &gt; two time upper limit normal Visit 1 ) , hepatic impairment ( AST ALT &gt; three time upper limit normal Visit 1 ) , clinically significant cardiovascular , respiratory , psychiatric disease per investigator 's judgment 11 . Postvoid residual ( PVR ) urine volume &gt; 150 mL screen 12 . Any condition judgment investigator would interfere patient 's ability provide inform consent , comply study instruction , place patient increase risk , might confound interpretation study result 13 . Previously receive intravesical liposome 14 . Urinary tract prostatic infection past 90 day study entry 15 . Active genital herpes vaginitis 16 . Urethral diverticulum 17 . Pelvic malignancy within past five year 18 . History cyclophosphamide chemical cystitis , tuberculosis pelvic radiation 19 . History bladder prostate tumor ( benign malignant ) 20 . Uncontrolled diabetes 21 . Has condition would preclude treatment due contraindication and/or warning product labeling</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Interstitial Cystitis</keyword>
	<keyword>Painful Bladder Syndrome</keyword>
	<keyword>Bladder Pain Syndrome</keyword>
	<keyword>Liposome</keyword>
	<keyword>LP-08</keyword>
</DOC>